The US Food and Drug Administration and the European Medicines Agency jointly issued principles for safe and responsible use of artificial intelligence in developing medicines, aiming to speed up innovation while safeguarding patients.
The principles, issued on Wednesday, offer broad guidance on how AI should be used to generate and monitor evidence across a drug’s lifecycle, from early research and clinical trials to manufacturing and safety surveillance.
The move comes as regulators push to expand the use of AI in drug discovery and…
